2 completed, 1 terminated. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow Mitchell Horwitz, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant Naive T Cell Depleted Donor Lymphocyte Infusion - Hematological Malignancies | Phase 1 | Completed | Mitchell Horwitz, MD | 28 | 2012-06-01 | 2018-02-13 |
| Donor Enhancement With Plerixafor Post Myeloablative Allogeneic Transplant Plerixafor - Failure of Bone Marrow Graft | Phase 1 / Phase 2 | Completed | Mitchell Horwitz, MD | 41 | 2011-12-01 | 2017-04-25 |
| Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant Genotropin (Recombinant Human Growth Hormone) - Allogeneic Stem Cell Transplantation | Phase 1 | Terminated | Mitchell Horwitz, MD | 14 | 2008-09-01 | 2014-03-20 |
Growth Hormone (1) · Human Growth Hormone (1) · plerixafor (1)
United States (3)